Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Non-invasive pneumococcal pneumonia causes significant morbidity and mortality in older adults. Understanding pneumococcal sero-epidemiology in adults ≥50 years is necessary to inform vaccination policies and the updating of pneumococcal vaccines.
Methods: We conducted a systematic review and random-effects meta-analysis to determine the proportion of community-acquired pneumonia (CAP) in people ≥50 years due to pneumococcus and the proportion caused by pneumococcal vaccine serotypes. We searched MEDLINE, EMBASE and PubMed from 1 January 1990 to 30 March 2021. Heterogeneity was explored by subgroup analysis according to a) patient group (stratified versus age) and depth of testing, b) detection/serotyping method, and c) continent. The protocol is registered with PROSPERO (CRD42020192002).
Findings: Twenty-eight studies were included (34,216 patients). In the period 1-5 years after introduction of childhood PCV10/13 immunisation, 18% of CAP cases (95% CI 13-24%) were attributable to pneumococcus, with 49% (43-54%) of pneumococcal CAP due to PCV13 serotypes. The estimated proportion of pneumococcal CAP was highest in one study that used 24-valent serotype-specific urinary-antigen detection (ss-UAD)(30% [28-31%]), followed by studies based on diagnostic serology (28% [24-33%]), PCR (26% [15-37%]), ss-UAD14 (17% [13-22%]), and culture alone (14% [10-19%]). A higher estimate was observed in Europe (26% [21-30%] than North America (11% [9-12%](<0·001). PCV13-serotype estimates were also influenced by serotyping methods.
Interpretation: Non-invasive pneumococcal CAP and vaccine-type pneumococcal CAP remains a burden in older adults despite widespread introduction of pneumococcal infant immunisation. Studies heavily reliant on ss-UADs restricted to vaccine-type serotypes may overestimate the proportion of potentially vaccine-preventable pneumococcal pneumonia. Sero-epidemiological data from low-income countries are lacking.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790487 | PMC |
| http://dx.doi.org/10.1016/j.eclinm.2022.101271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distribution of serotypes and antibiotic resistance profiles of Streptococcus pneumoniae in hospitalized adult patients: aretrospective multicenter surveillance in China (2018-2019).
BMC Infect Dis
August 2025
Department of Clinical Microbiology, Peking University People's Hospital, Beijing, China.
Background: Streptococcus pneumoniae (S. pneumoniae) remains a major cause of community acquired pneumonia (CAP), particularly among older adults. In China, pneumococcal infections pose a substantial disease burden, with rising antibiotic resistance.
View Article and Find Full Text PDFThe global proteome of EF3030 under nutrient-defined conditions.
Front Cell Infect Microbiol
August 2025
Department of Molecular Genetics and Infection Biology, Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany.
Introduction: is a human pathobiont that asymptomatically colonizes the upper respiratory tract but can cause severe diseases such as pneumonia, sepsis, and meningitis, as well as non-invasive infections like otitis media and sinusitis. It thrives in the nutrient-limited environment of the nasopharynx and has evolved mechanisms to manage host-induced stress and regulate protein levels accordingly.
Methods: To investigate the molecular biology of under in vitro and infection-relevant conditions, a suitable cultivation medium is essential for reproducible experiments.
Genomic analysis and pneumococcal population dynamics across PCV implementation in South Korea, 1997-2023.
Microb Genom
July 2025
Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
, a clinically significant pathogen, causes invasive diseases in children and older adults. Pneumococcal conjugate vaccines (PCVs) have substantially reduced the incidence of vaccine serotype (VT) pneumococcal diseases. However, serotype replacement, characterized by the emergence of non-vaccine serotypes (NVTs), presents a persistent challenge to disease prevention.
View Article and Find Full Text PDFAccelerating pneumococcal protection in India: The case for rapid adoption of PCV20 across pediatric and adult populations.
Indian J Med Microbiol
August 2025
Departments of Clinical Microbiology, General Medicine, Geriatics, Respiratory medicine and Rheumatology, Christian Medical College, Vellore, India. Electronic address:
Background: Streptococcus pneumoniae poses a significant public health burden, particularly in India, where invasive and non-invasive forms contribute to high morbidity and mortality. Rapid disease progression and limitations of antimicrobial therapy underscore the need for preventive strategies. Pneumococcal vaccines, especially the 20-valent conjugate vaccine (PCV20), offer robust protection against diverse serotypes, reduce nasopharyngeal carriage, and promote herd immunity.
View Article and Find Full Text PDFSerotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.
Front Public Health
June 2025
Vaccines R&D/Infectious Disease, GSK, Wavre, Belgium.
Introduction: Widespread implementation of pneumococcal conjugate vaccines (PCVs)-namely the 7-valent PCV (PCV7), 10-valent pneumococcal non-typeable protein D conjugate vaccine (PHiD-CV), and 13-valent PCV (PCV13)-in infant national immunization programs has reduced pneumococcal diseases in children, including invasive pneumococcal disease (IPD), acute otitis media (AOM), and community-acquired pneumonia (CAP). However, as the use of PCV impacts pneumococcal epidemiology, identifying the serotypes associated with remaining disease is crucial to guide future vaccination strategies for this population.
Methods: We systematically searched the literature for observational studies (2006-2020) on pneumococcal serotype distribution in IPD, AOM, and CAP among ≤5-year-old children post-PCV introduction.